GSK Financial Analysis
GSK Key Indicators
GSK Income Statement
GSK Balance Sheet
GSK Cash Flow
Quarterly
| FY2024Q4 | FY2024Q3 | FY2024Q2 | FY2024Q1 | FY2023Q4 | FY2023Q3 | FY2023Q2 | FY2023Q1 | FY2022Q4 | FY2022Q3 | FY2022Q2 | FY2022Q1 | FY2021Q4 | FY2021Q3 | FY2021Q2 | FY2021Q1 | FY2020Q4 | FY2020Q3 | FY2020Q2 | FY2020Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Cash Flow from Operating Activities | 2.73B -25.79% | 2.78B -0.05% | 1.09B -19.14% | 1.19B 943.11% | 3.68B 99.49% | 2.79B 83.97% | 1.35B 105.34% | 114.16M -96.55% | 1.84B -60.60% | 1.51B -46.29% | 658.72M -14.56% | 3.31B 884.04% | 4.68B 0.78% | 2.82B 164.11% | 770.93M -73.97% | 336.22M -70.37% | 4.64B 15.81% | 1.07B -64.73% | 2.96B 115.38% | 1.13B |
Funds from Operations | 1.14B -75.17% | 1.02B -63.82% | 1.89B -26.28% | 2.35B -23.53% | 4.59B 190.91% | 2.81B 56.46% | 2.57B 273.76% | 3.07B -28.81% | 1.58B 73.05% | 1.80B -40.00% | 687.63M -20.07% | 4.31B 72.79% | 912.32M -84.90% | 2.99B 38.17% | 860.31M -32.26% | 2.50B 4.41% | 6.04B 28.49% | 2.17B -25.99% | 1.27B -24.04% | 2.39B |
Change in Working Capital | 1.59B -273.04% | 1.77B -7081.98% | -801.04M -34.21% | -1.16B -60.85% | -917.35M -447.85% | -25.31M -91.04% | -1.22B 4110.84% | -2.96B 194.02% | 263.72M -92.99% | -282.32M 61.29% | -28.91M -67.65% | -1.01B -53.45% | 3.76B -368.66% | -175.04M -84.08% | -89.38M -105.28% | -2.16B 71.96% | -1.40B 101.58% | -1.10B -1214.91% | 1.69B -669.85% | -1.26B |
Net Cash Flow from Investing Activities | -1.49B -654.57% | -989.47M 52.72% | 939.80M -170.46% | -254.91M -63.11% | 269.37M -142.01% | -647.88M -83.54% | -1.33B -143.27% | -691.05M -85.70% | -641.13M 30.70% | -3.94B 144.99% | 3.08B -1445.77% | -4.83B 6161.98% | -490.53M 540.50% | -1.61B 119.64% | -229.04M -106.54% | -77.16M -20.64% | -76.58M -84.58% | -731.69M 19.19% | 3.50B -572.17% | -97.24M |
Capital Expenditures - Net | 1.37B 42.18% | 966.06M 57.09% | 553.79M -15.54% | 678.49M 7.85% | 963.28M 49.97% | 614.98M 45.22% | 655.67M 23.60% | 629.11M -19.95% | 642.31M 44.00% | 423.48M -72.86% | 530.50M -25.52% | 785.89M -5284.90% | 446.06M 74.13% | 1.56B 93.76% | 712.27M -552.18% | -15.16M -105.27% | 256.16M -54.76% | 805.25M 78.00% | -157.52M -121.58% | 287.88M |
Acquisition & Disposal of Business Sold/(Acquired) | -79.43M 18.50% | -3.90M -95.03% | -49.20M -97.05% | -915.64M 12465.45% | -67.03M -43.93% | -78.45M -97.80% | -1.67B 10121.66% | -7.29M -643.35% | -119.55M -1367.37% | -3.57B 43099.70% | -16.34M -46.81% | 1.34M -67.56% | 9.43M -76.95% | -8.27M -158.26% | -30.73M -109.53% | 4.13M -111.14% | 40.93M -61.68% | 14.20M -85.42% | 322.48M 597.00% | -37.10M |
Investments - Associated Co & JVs - Sold/(Purchased) | -20.50M -133.70% | -31.21M | 0.00 | 0.00 -100.00% | 60.83M | 0.00 -100.00% | 0.00 | 1.21M | 0.00 | -1.18M | 0.00 -100.00% | 0.00 | 0.00 -100.00% | 0.00 | 385.47M | 0.00 -100.00% | -3.96M -38.44% | 0.00 -100.00% | 0.00 -100.00% | -1.28M |
Net Cash Flow from Financing Activities | -762.30M -81.42% | -1.56B -28.91% | -1.66B -468.72% | -1.25B 421.58% | -4.10B 252.25% | -2.19B -17.25% | 449.21M -102.70% | -240.47M -102.23% | -1.17B -65.05% | -2.65B 49.14% | -16.62B 716.02% | 10.81B -712.23% | -3.33B 38.12% | -1.77B -67.54% | -2.04B -27.00% | -1.77B 44.31% | -2.41B -21.95% | -5.47B 151.90% | -2.79B 287.58% | -1.22B |
Dividends Paid | 784.08M 11.20% | 795.73M 10.91% | 822.48M 18.01% | 720.34M 6.87% | 705.08M -8.02% | 717.48M -13.48% | 696.96M -52.04% | 674.05M -47.21% | 766.55M -40.19% | 829.31M -36.73% | 1.45B -9.60% | 1.28B -2.06% | 1.28B 2.60% | 1.31B 7.37% | 1.61B 13.29% | 1.30B 8.27% | 1.25B 3.14% | 1.22B 5.35% | 1.42B -2.90% | 1.20B |
Stock - Total - Issuance/(Retirement) - Net | 0.00 -100.00% | 1.30M | 1.26M 0.82% | 22.83M 213.27% | 1.24M | 0.00 -100.00% | 1.25M | 7.29M -54.72% | 0.00 -100.00% | 9.41M 582.77% | 0.00 -100.00% | 16.09M -22.14% | 1.35M 2.06% | 1.38M -46.60% | 5.59M 50.13% | 20.67M -29.76% | 1.32M -89.74% | 2.58M -73.83% | 3.72M -51.75% | 29.43M |
Minority Interests & Joint Ventures - Net | 0.00 | 10.40M | 1.26M | 0.00 -100.00% | 0.00 | 0.00 | 0.00 | 8.50M -20.76% | 0.00 | 0.00 | 0.00 | 10.73M 11.23% | 0.00 | 0.00 | 0.00 | 9.65M 151.29% | 0.00 | 0.00 -100.00% | 0.00 | 3.84M |
Debt - LT & ST - Issuance/(Retirement) | 240.86M -106.88% | -785.33M -43.48% | -751.84M -160.75% | -481.92M -209.92% | -3.50B 550.45% | -1.39B -1.90% | 1.24B -108.17% | 438.43M -96.33% | -537.99M -72.93% | -1.42B 287.76% | -15.15B 2654.00% | 11.93B -16135.60% | -1.99B 160.89% | -365.25M -90.18% | -550.27M -26.79% | -74.41M -65.59% | -761.89M -52.45% | -3.72B 303.35% | -751.64M -178.50% | -216.23M |
Net Change in Cash | 480.44M -338.91% | 193.73M -950.56% | 367.09M -7.45% | -342.41M -59.95% | -201.10M -335.03% | -22.78M -99.52% | 396.65M -109.49% | -855.01M -109.19% | 85.56M -89.82% | -4.79B 173836.74% | -4.18B 219.41% | 9.30B -698.29% | 840.90M -60.35% | -2.76M -99.95% | -1.31B -135.79% | -1.55B 1079.43% | 2.12B 642.20% | -5.19B -2173.11% | 3.66B -21984.92% | -131.79M |
Free Cash Flow | 1.27B -52.90% | 1.69B -21.67% | 536.13M -21.53% | 476.84M -190.26% | 2.70B 180.96% | 2.16B 127.14% | 683.20M 454.56% | -528.31M -121.11% | 962.29M -74.84% | 949.30M -18.59% | 123.20M -651.31% | 2.50B -1751.03% | 3.82B 8.52% | 1.17B 404.79% | -22.35M -100.91% | -151.57M -121.82% | 3.52B 16.62% | 230.99M -90.61% | 2.46B 340.61% | 694.75M |
Free Financial AI Agent for Investment
Ask any investment related question and get answer instantly
Is GSK earnings result positive or negative?How should I trade on GSK earnings?GSK FAQs
What is GSK's PE Ratio in 2025/4/4?
GSK's PE ratio in April 4, 2025 is 22.79. This indicates the price investors are willing to pay for $1 of earnings.
What is GSK's PS Ratio in 2025/4/4?
GSK's PS ratio in April 4, 2025 is 1.84. This indicates how much investors are willing to pay for each dollar of the company's sales.
What is GSK's Dividend Yield in 2024/Q4?
GSK's Dividend Yield in 2024/Q4 is 4.52%. This represents the return on investment from dividends relative to the stock price.
What is GSK's Gross Margin in 2024/Q4?
GSK's Gross Margin in 2024/Q4 is 68.93. Gross Margin is typically calculated as (Revenue - Cost of Goods Sold) / Revenue and is a key indicator of a company's financial health and efficiency in managing production costs.
Free Financial AI Agent for Investment
Ask any investment related question and get answer instantly
Is GSK earnings result positive or negative?How should I trade on GSK earnings?